Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Maher, T M, Goldin, J G, Hood, J, Pitman, J, de los Rios, M, Hobbs, B P, Yu-Lin, A B, Buendia-Roldan, I, Thien, F, Song, J W, Perea, P C, Ramírez-Rivera, A, DiFrancesco, A · 2025 · The Lancet Respiratory Medicine

Abstract

Phase 2a proof-of-concept trial in IPF that reported acceptable safety and between-group differences favoring taladegib on percent predicted FVC, HRCT total lung capacity, and quantitative interstitial lung disease measures over 12 weeks.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(25)00239-5

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 31 references

Cited by

See all 10

Metadata

Authors
Maher, T. M., Goldin, J. G., Hood, J., Pitman, J., de los Rios, M., Hobbs, B. P., Yu-Lin, A. B., Buendia-Roldan, I., Thien, F., Song, J. W., Perea, P. C., Ramírez-Rivera, A., & DiFrancesco, A.
Affiliations
  • University of Southern California (US)
  • University of California, Los Angeles (US)
  • National University of Malaysia (MY)
  • Box Hill Hospital (AU)
  • Asan Medical Center (KR)
  • Intarcia Therapeutics (United States) (US)
Corresponding author
DiFrancesco, A
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2025-11
Volume
13
Issue
11
Pages
1001-1010
ISSN
2213-2600 (ISSN-L)
OpenAlex
W4414708803
Cited by
9
References
31
Citations by year
2026: 8 · 2025: 1
FWCI
5.46
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
idiopathic pulmonary fibrosis, Hedgehog signaling, Hedgehog pathway inhibitors, antifibrotic therapy, forced vital capacity, dysgeusia, drug safety, interstitial lung disease
MeSH terms
Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyridines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. https://app.cochat.ai/papers/10.1016/s2213-2600(25)00239-5
The paper
Maher, T. M., Goldin, J. G., Hood, J., Pitman, J., de los Rios, M., Hobbs, B. P., Yu-Lin, A. B., Buendia-Roldan, I., Thien, F., Song, J. W., Perea, P. C., Ramírez-Rivera, A., & DiFrancesco, A. (2025). Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(25)00239-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.